HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that Abbott Laboratories has filed a lawsuit against the Company in the United States District Court for the District of Delaware alleging patent infringement related to IMPAX's filing of an Abbreviated New Drug Application (ANDA) for generic versions of Depakote® ER 250mg and 500mg tablets. IMPAX's submission includes a Paragraph IV certification stating the Company believes its product does not infringe Abbott's listed patents or that the listed patents are invalid.
